50MEDIUM

NSB

NEUROSCIEN FPO [NSB]
NeuroScientific Biopharmaceuticals Limited engages in the research and development of biomedical products targeting neurodegenerative conditions. Its lead product is the EmtinB drug for the treatment of optic nerve diseases, such as glaucoma. The company also develops StemSmart platform technology to treat inflammatory immune disorders. NeuroScientific Biopharmaceuticals Limited was incorporated in 2002 and is based in Perth, Australia.
Healthcare · ASX Small Cap
$0.0870 +6.1%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical59
Catalyst50
Sentiment50
Fundamental70
Momentum80
Risk Gate46
Get alerts when NSB's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track NSB — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • MACD momentum is picking up steam
  • On a tear — up 11.5% over the last 5 days
  • Volume-price trend says buyers are quietly accumulating — price hasn't caught up yet
  • Volatility is expanding fast — choppy price action, so buckle up
  • Strong cash runway (18 quarters)
  • 4C filed 2026-01-29
  • Very high P/S ratio (91.0x)
  • Strong revenue growth (+129%)
  • Small-cap ($20-100M)
  • Sentiment is mixed — no strong consensus either way
  • Strong long-term momentum — up 72% over the past year (excluding last month)
  • Revenue growing at +129% — the top line is moving in the right direction
  • The bigger volume days are the up days — volume-weighted momentum is positive (9.83%/day)
  • Altman Z-Score grey zone (1.92, low-confidence approx)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about NSB
"What's driving NSB's score?" "How does NSB compare to peers?" "Key risks for NSB?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE StemSmart Manufacturing Scale-Up Transfer Advances
NONE Half Yearly Report and Accounts
NONE Company Presentation
LOW Quarterly Activities/Appendix 4C Cash Flow Report

Recent ASX Announcements

2026-03-16 StemSmart Manufacturing Scale-Up Transfer Advances
2026-02-25 Half Yearly Report and Accounts PRICE SENSITIVE
2026-02-15 Company Presentation
2026-01-29 Quarterly Activities/Appendix 4C Cash Flow Report PRICE SENSITIVE

Key Metrics

$28.9M
Market Cap
221K
Avg Volume
0.9x
Vol Ratio
$0.03 — $0.26
52-Week Range
N/A
Short Interest
18 qtrs
Cash Runway
-29.6%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 73%
LLeader vs LaggardlaggardRS: -5
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #36 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:NSB vs ATXNSB vs PNVNSB vs IMM
Scout Pro — Deeper Analysis for NSB
Try Pro free for 30 days
Share this analysis

Track NSB and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required